OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia

Clarification on the news article by Commercial Times
July 30, 2018
OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities
September 3, 2018
  1. Date of occurrence of the event: Aug 15, 2018
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Cause of occurrence: OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia (No. 2016229136).
  6. Countermeasures: None
  7. Any other matters that need to be specified: None